These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29765213)

  • 1. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
    Kardos P; Mokros I; Sauer R; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1455-1468. PubMed ID: 29765213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
    Yuan L; Dai X; Yang M; Cai Q; Shao N
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
    Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
    Michels G; Erdmann E; Pfister R
    Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
    Janjua S; Fortescue R; Poole P
    Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
    Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
    Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast in the management of chronic obstructive pulmonary disease.
    Lipari M; Benipal H; Kale-Pradhan P
    Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
    Reid DJ; Pham NT
    Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Considerations for Roflumilast: A New Treatment for COPD.
    Kelly Freeman ML
    Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 18. Roflumilast for COPD.
    Izquierdo JL; Aparicio J
    Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
    Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
    Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.